Asia-Pacific Active Implantable Medical Devices Market

Asia-Pacific Active Implantable Medical Devices Market Size (2024 to 2029)

The Asia-Pacific active implantable medical devices market size is anticipated to grow at an 8.45% CAGR from 2024 to 2029 and be worth USD 8.18 billion by 2029 from USD 5.46 billion in 2024.

Various factors such as the increasing elderly population, high rate of cardiovascular disease, and other chronic diseases drive the APAC active implantable medical devices market. According to the WHO, around 87.9 million people die from cardiovascular disease (CVD) each year, representing 32% of all deaths worldwide. In 2016, the estimated prevalence of CVDs in India was reported to be significant, with 55 million people diagnosed. According to the Australian heart foundation, one in six Australians suffers from CVD, accounting for nearly 4.2 million Australians. These numbers represent approximately 16% of the total Australian population. Additionally, factors such as the availability of investments and funds to develop technologically advanced products and favorable reimbursement scenarios in developed countries are expected to drive the APAC regional market during the forecast period positively.

In addition, there is an increase in cases of neurological disorders such as Parkinson's disease, epilepsy, and dystopia in emerging economies like India. Applications of neurostimulators are effective in treating these neurological diseases in the long term. According to the Global Burden of Disease report, the prevalence rate has increased by 16% for Parkinson's disease, 2.5% for Alzheimer's disease, and 9% for brain and nervous system-associated cancer. It has also been reported that nearly four per 1,000 people from Parkinson's disease in Australia, the disease incidence have raised to one per 100 people above the age of 60. In Australia, around 80,500 people live with Parkinson's disease, and one in five diagnosed people is less than 50 years old. According to a recent study concluded in India, the North India population is 68 per 100,000 individuals. All these factors are expected to accelerate the growth of the overall studied market in the coming years.

However, several issues related to the use of active implantable medical devices, such as device failures and cybersecurity concerns, may hamper the market's growth shortly. In addition, the unavailability of reimbursement policies, poor healthcare facilities, and the high cost of implants is expected will affect the market growth rate.

This research report on the Asia-Pacific active implantable medical devices market has been segmented and sub-segmented into the following categories.

Asia-Pacific Active Implantable Medical Devices Market - By Product:

• Implantable Cardioverter Defibrillators
  • Transvenous Implantable Cardioverter Defibrillators
    • Biventricular Implantable Cardioverter Defibrillators (ICDs)/Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
    • Dual-Chamber Implantable Cardioverter Defibrillators
    • Single-Chamber Implantable Cardioverter Defibrillators
  • Subcutaneous Implantable Cardioverter Defibrillator
• Implantable Cardiac Pacemakers
• Ventricular Assist Devices
• Implantable Heart Monitors/Insertable Loop Recorders
• Neurostimulators
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Gastric Electrical Stimulators
• Implantable Hearing Devices
  • Active Hearing Implants
  • Passive Hearing Implants

Asia-Pacific Active Implantable Medical Devices Market - By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Based on region, the market in the Asia-Pacific region is expected to grow at the highest CAGR due to the rise in geriatric population, growth in the occurrence of chronic diseases, rise in healthcare spending, healthcare reforms for infrastructural development, growth in the demand for advanced technologies to develop cutting-edge products, and less strict regulations.

Countries like China and India have a large geriatric population, and the healthcare infrastructure in these countries is improving, thus illustrating immense healthcare market potential. The world's second-largest economy seen in China will grow up to an expected market size of US $ 3 billion by the year 2027, with an impressive CAGR of 6.9% during the analysis period. China is likely to dominate the APAC active implantable medical devices market due to its large population, increasing prevalence of cardiovascular and neurological diseases, accessibility of advanced technologies, and the presence of less stringent rules for product approval in the region. According to Disease Control and Prevention (CDC), approximately 3.6 to 7.5 million people suffer from atrial fibrillation.

The active implantable medical device market in India is expected to experience significant growth owing to the high prevalence of chronic diseases, less strict rules, and favorable reimbursement policies in the region. According to the Global Burden of Disease study, the death rate from cardiovascular disease was 275 per 100,000 people in India, higher than the world average of 236.

Other notable geographic markets are Japan and Australia, each with an annual growth forecast of 6% and 7.8%. Japan is expected to experience steady growth owing to the increased geriatric population suffering from CVD ailments. In addition, the region is affected by heart disease, and around 20 million people are diagnosed with the disease in the region.

KEY MARKET PLAYERS:

Companies playing a promising role in the Asia-Pacific active implantable medical devices market profiled in the report include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC., Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd.